Gabapenteg

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gabapenteg

Quick Facts

Property Description
Active Ingredient Gabapentin
Route / Form Oral (Capsule, Tablet, Oral Solution)
Pharmacological Class Anticonvulsant / Anti-epileptic drug (AED)
Origin / Type Synthetic gamma-Aminobutyric Acid (GABA) analogue
General Purpose Stabilizing nerve communication and reducing nerve excitability

What Type of Medicine Is Gabapenteg and What Does it Contain?

Gabapenteg is a prescription medicinal product containing the active ingredient Gabapentin, which is formally classified as an anticonvulsant or anti-epileptic drug (AED). This compound is a single-ingredient, synthetic molecule that acts as a structural analogue of gamma-Aminobutyric Acid (GABA), the major inhibitory neurotransmitter in the central nervous system. This chemical relationship confirms the drug's intended action within the nervous system. Its identity as a central nervous system depressant is widely recognized.

How is Gabapentin Classified and What is its General Purpose?

Gabapentin is fundamentally categorized as an anticonvulsant because its primary function is to stabilize and modulate abnormal electrical signaling in the nervous system. The drug achieves this by binding with high affinity to the alpha2delta subunit of voltage-dependent calcium channels on nerve cells. This mechanism reduces the release of certain excitatory neurotransmitters, thereby exerting a calming effect on overexcited nerves. This process is clinically recognized for its ability to ease nerve discomfort and help control aberrant neuronal activity.

What Forms are Available for Gabapenteg?

The medication is administered via the oral route and is supplied in a variety of immediate-release dosage forms, including a capsule, a standard tablet, and an oral solution. This formulation diversity is available to suit patient needs. Prominent pharmaceutical products that share the Gabapentin active ingredient include Neurontin and Gralise. Importantly, standard Gabapentin products are distinct from the extended-release prodrug, Gabapentin enacarbil, which has different pharmacological properties.

What side effects are possible with Gabapenteg?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Gabapenteg (Gabapentin) primarily around effects involving the Nervous System and specific warnings for serious systemic reactions.

Frequency-Classified Adverse Reactions

The most frequently expected adverse reactions are classified based on incidence rates observed in clinical trials, predominantly affecting the central nervous system. Very Common side effects, occurring in at least 1 in 10 individuals, include dizziness and somnolence (drowsiness). Reactions classified as Common (occurring in fewer than 1 in 10 people) include ataxia (lack of coordination), fatigue, peripheral edema (swelling of extremities), and nystagmus (involuntary eye movement).


Serious Adverse Reactions and Key Constraints

Official labeling mandates specific warnings for several rare but clinically significant adverse reactions. These include the risk of Suicidal Behavior and Ideation and the potential for severe, life-threatening allergic reactions like DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) and anaphylaxis.

Regulatory authorities also highlight the risk of Respiratory Depression (serious breathing difficulties), especially when Gabapenteg is used concurrently with other central nervous system depressants, such as opioids. Furthermore, abrupt or rapid discontinuation, particularly in patients being treated for seizure disorders, may increase the risk of precipitating seizures.


Population-Specific Safety Notes

Safety considerations are noted for specific groups. Clearance of the medicine is dependent on renal function; consequently, dosage adjustments are often necessary for older adults and patients with impaired kidney function. In pediatric patients (aged 3–12 years), the label requires specific monitoring for Neuropsychiatric Adverse Reactions including hostility and emotional lability.

Overdose and Emergency Response

The official regulatory profile for Gabapenteg (Gabapentin) overdose is defined by manifestations of Central Nervous System (CNS) depression. Documented presentations strictly align with label statements, including significant drowsiness (somnolence), lethargy, dizziness, slurred speech (dysarthria), and double vision (diplopia). Gastrointestinal effects, such as diarrhea, have also been noted. While single-agent overdose has been reported without acute life-threatening toxicity at exposures up to 49 grams, the risk of severe outcomes, including coma and respiratory depression, increases significantly when the medicine is co-ingested with other CNS depressants.

When to seek immediate medical help:

Immediate medical attention should be sought if an overdose is suspected, with instruction to contact emergency medical services. Treatment is strictly symptomatic and supportive care, as no specific antidote is known for Gabapenteg overdose. Hemodialysis may be indicated as a procedural step for drug removal, particularly in patients with significant renal impairment whose reduced kidney function affects Gabapenteg elimination. Other supportive measures, such as gastric lavage or activated charcoal, may be considered to reduce absorption of the unabsorbed drug.

Therapeutic Uses of Gabapenteg

Gabapenteg (Gabapentin) is generally used in two primary therapeutic areas that involve managing symptoms related to heightened physiological activity. The medication is commonly used to help manage symptoms associated with partial onset seizures in adults and pediatric patients aged 3 years and older, and for easing certain chronic neuropathic pain syndromes.

For seizure management, it is primarily applied as an adjunctive therapy to manage symptoms of increased neurological or muscular activity associated with these manifestations. For pain, it is relevant for conditions like postherpetic neuralgia (PHN), a condition presenting with systemic or localized discomfort that may continue following a shingles episode. The medication is applied in addressing distressing symptoms like burning, shooting, and stabbing nerve pain.

“The primary goal is to provide supportive relief that helps patients cope more steadily with difficult episodes.”

This supports the goal of easing the overall symptom burden by supporting the goal of easing the occurrence of recurrent seizure manifestations, while assisting with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Symptomatic Support for Neuropathic Pain Quick Fact: Support for Seizure Management
Target Symptoms: Burning, shooting, and stabbing nerve pain. Target Conditions: Partial onset seizures (adjunctive therapy).
Patient-Oriented Benefit: Supports functional stability and helps ease discomfort. Patient Group: Adults and pediatric patients aged 3 years and older.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Gabapenteg

The eligibility for Gabapenteg (Gabapentin) is strictly defined by regulatory criteria, encompassing absolute prohibitions and conditional restrictions.

Category Regulatory Eligibility Status
Contraindicated Populations Individuals with known hypersensitivity to gabapentin or any component of the formulation. Use is absolutely prohibited for patients who have previously developed a Severe Cutaneous Adverse Reaction (SCAR), such as DRESS, with its use.
Age-Related Eligibility Approved for adults with Postherpetic Neuralgia (PHN). Approved for partial onset seizures in adults and pediatric patients 3 years of age and older. Safety and effectiveness have not been established for PHN in pediatric patients or for seizures in children under 3 years old.
Condition-Specific Restrictions Renal Impairment: Use is allowed only with a mandatory dose adjustment based on the patient's estimated creatinine clearance ( CrCl), as the drug is cleared primarily by the kidneys. Hemodialysis patients require a supplemental dose. Older adults typically require the same CrCl-based adjustment due to age-related decline in kidney function.
Reproductive Eligibility Pregnancy: Not generally recommended; use is conditional on the potential benefit clearly justifying the potential risk to the fetus. Lactation: Use is conditional; gabapentin passes into breast milk and is permitted only if benefits outweigh risks to the infant.

What should I know about interactions with other medicines?

Gabapenteg’s official interaction profile is defined by documented pharmacodynamic potentiation and specific pharmacokinetic modifications related to absorption and clearance. No drug-drug combinations are formally classified as contraindicated in regulatory labeling.

Drug–Drug Interactions

Co-administration with other Central Nervous System (CNS) depressants presents a significant pharmacodynamic interaction, leading to an increased risk of additive effects such as sedation and respiratory depression. This category includes opioids, certain antihistamines, and alcohol. Pharmacokinetic data shows that Morphine co-administration may increase the plasma concentration of Gabapenteg, while Gabapenteg may reduce the exposure of Hydrocodone. Conversely, official documentation confirms the absence of a significant metabolic interaction with several commonly used antiepileptic drugs, including phenytoin, carbamazepine, valproic acid, and phenobarbital.

Administration Timing and Substance Interactions

A critical pharmacokinetic constraint involves antacids containing aluminum and magnesium hydroxides. These products reduce the oral bioavailability of Gabapenteg by approximately 20%. To mitigate this effect, official labeling specifies a mandatory timing rule: Gabapenteg must be administered at the earliest two hours following the use of such antacids.

Population-Specific Notes

The risk of respiratory depression due to pharmacodynamic potentiation with CNS depressants is noted as being of greater concern in patients aged 65 years or older or those with pre-existing lung conditions. Additionally, patients with renal impairment require consideration, as Gabapenteg’s slower clearance in this population may affect its exposure.

Mechanism of Action

️ How Gabapenteg Works: Mechanism of Action

α2δ Subunit Modulation and Calcium Channels

Gabapenteg acts primarily by binding with high affinity to the α2δ subunit of voltage-dependent calcium channels (VDCCs) on presynaptic nerve terminals. This molecular interaction initiates a cascade that reduces the number of functional channels available at the cell membrane, which limits the entry of calcium ions (Ca^2+) required for signal transmission.

Dampening of Excitatory Neurotransmitter Release

The resulting restriction of calcium flow directly reduces the release of excitatory neurotransmitters, such as glutamate, into the synapse. This is a targeted action that suppresses the output of key chemical messengers in the central nervous system.

Stabilization of Hyperexcitable Circuits

The overall physiological effect of reducing excitatory signaling is the stabilization of hyperexcitable nerve circuits within the brain and spinal cord. By modulating the α2δ subunit, the drug engages mechanisms that dampen excessive nerve firing, resulting in reduced signaling and decreased nerve excitability.

Dosage and Administration Information

How to Use Gabapenteg: Administration Guidelines

Gabapenteg (Gabapentin) is administered via the oral route only. It is available as immediate-release capsules, tablets, and an oral solution. Use of the medicine follows strict schedules to maintain consistent levels in the body.

Dosing and Frequency

The medication is typically taken as a divided daily dose, usually administered three times a day (TID). This multiple daily dosing is essential; to maintain efficacy, the time interval between any two doses must not exceed 12 hours.

Indication Starting Dose (Adults) Maintenance Range (Adults)
Partial Seizures 300 mg TID on Day 1 900 mg/day up to 3,600 mg/day (divided TID)
Postherpetic Neuralgia (PHN) 300 mg on Day 1 (single dose) Up to 1,800 mg/day (divided TID)

General and Population-Specific Instructions

  • Administration: Gabapenteg may be taken with or without food. Capsules and tablets must be swallowed whole.
  • Initiation and Discontinuation: Therapy must begin with a low starting dose and be gradually titrated (increased) to the target dose. Similarly, the medicine must not be stopped abruptly; the dose must be gradually tapered over a minimum period of one week.
  • Renal Function: A dose reduction is required for all patients with reduced creatinine clearance (compromised kidney function). Specific dosing adjustments are necessary based on the individual's level of renal impairment.
  • Pediatric Use: For pediatric patients with epilepsy, dosing is calculated based on body weight (mg/kg/day).

Recent Clinical Evidence

Evidence for Use in Partial Onset Seizures

Gabapenteg was studied for its use as an add-on therapy for partial onset seizures in short-term randomized controlled trials (RCTs). Researchers observed participants already taking other seizure medications and focused on outcomes measuring the change in seizure frequency. Findings describe patterns where participants receiving Gabapenteg documented differences in seizure frequency measurements compared to the placebo group. Information on long-term outcomes is not well established beyond the observation periods, and comparative evidence against some newer anti-epileptic drugs is lacking.


Evidence for Use in Postherpetic Neuralgia (PHN)

For Postherpetic Neuralgia (PHN)—a condition presenting with outcomes related to physical discomfort—Gabapenteg was evaluated in multiple short-term, placebo-controlled randomized trials. Research examined patient-reported outcomes describing discomfort, such as daily pain intensity and sleep interference measurements. Data show patterns related to participants receiving Gabapenteg documenting differences in pain scores between the groups. Evidence is limited for using Gabapenteg for neuropathic pain conditions other than PHN, and the sustained stability of pain measurements beyond a few months is not fully established.


Long-Term Studies and Maintenance of Response

Research has explored the durability of observed patterns through long-term open-label extension studies, primarily for seizure management. While these studies offer extended follow-up, information on long-term outcomes for either indication is not fully established, and certainty remains low concerning outcomes over multiple years of use.


Evidence in Specific Patient Populations

For seizure management, Gabapenteg was studied for use in pediatric patients aged 3 years and older. Controlled trials for PHN included older adults. However, data for certain groups remain insufficient, especially for children under the age of three for seizure treatment and for exploring patterns in patients with specific comorbidities.


What Research Gaps and Uncertainties Remain

Several research limitation frames apply to the existing evidence. Comparative evidence against many alternative treatment options is lacking. Furthermore, findings were mixed or evidence is limited when exploring the use of Gabapenteg for types of neuropathic pain other than PHN. The results apply only to the populations studied, meaning research describes group patterns, not individual predictions outside the specific parameters of the trials.

Key Studies & References Neuropathic pain in adults: pharmacological management in non-specialist settings (NICE Guideline CG173)

Frequently Asked Questions (FAQ)

Common questions about Gabapenteg (FAQ)


Q: Does Gabapenteg have a black box warning?

The U.S. FDA requires specific warnings about the risk of serious breathing difficulties (respiratory depression) to be included in the official prescribing information. This risk is highlighted, especially when Gabapenteg is used concurrently with other Central Nervous System (CNS) depressants, such as opioids, or in individuals who have pre-existing respiratory risk factors.


Q: Can Gabapenteg interact with over-the-counter pain relievers?

Official labeling and regulatory documents do not list confirmed interactions between Gabapenteg (Gabapentin) and common, non-opioid over-the-counter pain relievers, such as acetaminophen or ibuprofen. However, information is provided in the official documentation regarding all medications and supplements.


Q: Does Gabapenteg require a special kind of prescription or monitoring?

In the United States, Gabapenteg (Gabapentin) is generally not classified as a controlled substance at the federal level. However, some state laws have classified it as a Schedule V controlled substance due to reports of potential misuse. This means the specific dispensing requirements can vary depending on location.


Q: Can Gabapenteg cause weight changes?

Yes, regulatory documents indicate that weight gain is a documented adverse reaction that has been reported in clinical trials, especially in adults and in children. This is considered one of the potential side effects listed in the official prescribing information.


Q: Is Gabapenteg thought to be habit-forming?

While the medication is not classified as a tightly regulated controlled substance by the federal government, official documents indicate a potential for misuse and dependence has been reported. This potential is often associated with higher doses in some individuals.


Q: What should be done if an interaction with another medication is suspected?

Official patient guidance states that the reporting of new or worsening symptoms suggesting a serious drug interaction warrants immediate medical attention. This action is specified for obtaining instruction and guidance.


Q: Does Gabapenteg affect kidney or liver function?

Gabapenteg is cleared from the body primarily by the kidneys, which is why official guidelines require a mandatory dose adjustment for patients with reduced kidney function. Although the drug is generally not broken down by the liver, a rare and serious allergic reaction called DRESS syndrome is documented to potentially affect liver function.


Q: Why is Gabapenteg sometimes prescribed for different reasons?

Gabapenteg is only approved by regulatory agencies for its two specific indications: treating partial onset seizures and postherpetic neuralgia (PHN). Official documents acknowledge that prescribers may use it for other, non-approved (off-label) conditions based on their clinical judgment and available evidence.


Q: Is Gabapenteg available as a generic medicine?

Yes, Gabapenteg is the product name for the active ingredient Gabapentin. The FDA has approved generic versions of this medicine, meaning that it is available from multiple manufacturers as immediate-release capsules, tablets, and oral solutions.


Q: What are the signs of a serious, but rare, side effect from Gabapenteg?

Serious, rare side effects noted in official warnings include symptoms like slowed or difficult breathing, bluish-colored skin or lips, and sudden changes such as confusion or unresponsiveness. Signs of a serious allergic reaction, such as DRESS syndrome, can include rash, fever, or swelling. The occurrence of these symptoms is outlined in regulatory instructions as warranting immediate medical attention.


Q: Is there a list of all potential side effects for Gabapenteg?

Official regulatory prescribing information includes a comprehensive list of all adverse reactions reported in clinical trials, classified by how often they occurred. While this document is the authoritative source for safety information, official guidance notes that the list may not include every single reaction a person might experience.


Q: Does Gabapenteg have any known interactions with herbal supplements?

Specific herbal supplements are not individually listed as official interactions in regulatory documents. However, official information notes that Gabapenteg may have additive effects when used with any product, including supplements, that can cause dizziness or drowsiness. This is due to the drug’s established effects on the Central Nervous System (CNS).


Q: Can Gabapenteg affect mental clarity or memory?

Yes, official safety information indicates that adverse effects involving the nervous system are possible. These reported effects can include difficulty concentrating or paying attention, occasional memory problems, and the emergence of unusual thoughts.


Q: Are there any warnings about driving or operating machinery while using Gabapenteg?

Yes, official warnings are mandated for this medication. Gabapenteg may cause side effects like dizziness, drowsiness (somnolence), and impaired coordination. Official warnings state that due to this potential, individuals using this medication must exercise caution before operating vehicles or complex machinery.


Q: Is Gabapenteg used for anxiety by some people?

Gabapenteg is not approved by regulatory bodies like the FDA for the treatment of anxiety disorders. Although official documents list anxiety as an off-label use, the drug is only formally recognized for treating partial onset seizures and postherpetic neuralgia.

How should Gabapenteg be stored and disposed of?

Storage Conditions and Stability

Gabapentin solid forms (capsules and tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and away from excess heat and moisture [1, 5]. The oral solution, however, requires refrigeration at 2 C to 8 C (36 F to 46 F) and must not be frozen [3].

All forms must be kept in a tight container or its original, tightly capped bottle [1, 3]. Regulatory documents specify that unused half-tablets must be discarded if not used within 28 days, and the oral solution must be discarded 6 months after opening [2, 3].

Disposal and Child Safety

As with all medicines, Gabapentin must be stored out of the sight and reach of children [4]. Official instructions require that unused or expired product be disposed of in accordance with local regulations [6]. The medicine should not be disposed of via wastewater unless specifically instructed to do so [6]. If a drug take-back program is unavailable, non-flush list medicines like Gabapentin should be mixed with an undesirable substance before being sealed and placed in household trash [7].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gabapenteg found in:

A-Z Index: